{"organizations": [], "uuid": "b8ca20f3815df7ef4e04bf6d6ab68a38ae666980", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-kamada-announces-collaboration-wit/brief-kamada-announces-collaboration-with-hospitals-to-evaluate-its-product-for-preemption-of-type-of-graft-versus-host-disease-idUSFWN1OZ0MF", "country": "US", "domain_rank": 408, "title": "BRIEF-Kamada Announces Collaboration With Hospitals To Evaluate Its Product For Preemption Of Type Of Graft-Versus-Host Disease", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-04T14:12:00.000+02:00", "replies_count": 0, "uuid": "b8ca20f3815df7ef4e04bf6d6ab68a38ae666980"}, "author": "", "url": "https://www.reuters.com/article/brief-kamada-announces-collaboration-wit/brief-kamada-announces-collaboration-with-hospitals-to-evaluate-its-product-for-preemption-of-type-of-graft-versus-host-disease-idUSFWN1OZ0MF", "ord_in_thread": 0, "title": "BRIEF-Kamada Announces Collaboration With Hospitals To Evaluate Its Product For Preemption Of Type Of Graft-Versus-Host Disease", "locations": [], "entities": {"persons": [{"name": "kamada", "sentiment": "none"}], "locations": [], "organizations": [{"name": "kamada ltd", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "preemption of type of graft-versus-host disease reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 4, 2018 / 12:12 PM / Updated 10 minutes ago BRIEF-Kamada Announces Collaboration With Hospitals To Evaluate Its Product For Preemption Of Type Of Graft-Versus-Host Disease Reuters Staff 1 Min Read \nJan 4 (Reuters) - Kamada Ltd: \n* KAMADA ANNOUNCES COLLABORATION WITH A CONSORTIUM OF PROMINENT HOSPITALS LED BY THE MOUNT SINAI HOSPITAL TO EVALUATE ITS ALPHA-1 ANTITRYPSIN PRODUCT FOR PREEMPTION OF STEROID REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE \n* KAMADA SAYS ANNOUNCED COLLABORATION WITH MOUNT SINAI ACUTE GVHD INTERNATIONAL CONSORTIUM \n* KAMADA LTD - RECEIVED EXCLUSIVE RIGHTS TO DEVELOP AND COMMERCIALIZE ALPHA-1 ANTITRYPSIN FOR PREEMPTION OF GVHD USING MAGIC BIOMARKERS \n* KAMADA SAYS STUDY OF ALPHA-1-ANTITRYPSIN WILL BE INITIATED IN Q1 OF 2018 \n* KAMADA LTD - TOP-LINE RESULTS FROM ALPHA-1-ANTITRYPSIN STUDY ARE EXPECTED TO BE AVAILABLE IN SECOND HALF OF 2019 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-04T14:12:00.000+02:00", "crawled": "2018-01-04T14:36:27.007+02:00", "highlightTitle": ""}